The project "Development of diagnostics and treatment opportunities based on Alpha-fetoprotein
and its receptor" is based on two “arms”:
1. development of AFP receptor measurement in biological fluids to detect a tumor (CA-62),
2. development of the drug delivery system based on native AFP, which as shown, can bring agent inside the tumor cell
(OncoShuttle™) via receptor-mediated endocytosis.
Competitive advantages: We have the Know-How to create native AFP complexes, which can penetrate into tumor cells,
and how to detect CA-62 in the blood and tissues.
Main point of the innovation: Usage of native AFP gives opportunity not only to bring the upload to tumor cell but to use
receptor-mediated endocytosis and put it inside the cell. Measurement of CA-62 allows to select patients to be cured.
Monitoring of CA-62 marker also makes evaluation of treatment possible.
IP protection potential - Know-How and Patents
Exit strategy - Strategic Partnering
Stage of the project - Clinical studies
Ricardo Moro and Viatcheslav Kondratiev hands shaking after signed agreement
Ricardo Moro M.D. (Canada) - scientist, doctor, honored researcher of Science, member of the editorial board of the scientific journal Tumor Biology, President of the International Society of Oncology and Biomarkers (ISOBM). Worked for a time as a full time researcher of the French National Cancer Institute (Institut de Recherches Scientiliques sur le Cancer,
Villejulf, France, which was part of the CNRS (Centre National de la Recherche Scientifique) and was in part supported by the Association pour la Recherche sur le Cancer (A.R.C.)). Further the French Cancer Institute was absorbed by the Pasteur
Viatcheslav Kondratiev M.Sc. (Canada/Russia), alumni of the Schulich School of Business of the York University, Toronto. Under his leadership the technology OncoShuttle has been developed and patented in the U.S., Europe and Russia (2011-
15). He is a CEO of the UCT (Universal Cancer Technologies) Research And Development.
Janneta Tcherkassova Ph.D. (Canada/Russia)-Internship in Sweden, member of the International Society of Oncology and
Biomarkers (ISOBM), head of the tumor markers laboratory at the Skolkovo Innovation Center, Moscow, Russia. For 13 years she worked in Canada as a head of the Department of Diagnostics. Under the leadership of Dr. Moro since 2003, developed approaches for test for early cancer detection. Beginning 2014 develops test in Russia as coordinator of laboratory test development. About 20 scientific publictions.
Sergei Tsurkan and Stéphane Gagné at the ENA2018 conference, Dublin, Ireland
Stéphane Gagné, MBA, Sherbrooke University (Canada) cumulates over 20 years of experience in the fields of cosmetics, nutritional supplements, cancer pharmaceutical products. He holds two bachelor degrees and a Master in Business
Administration. He has held senior positions in biotech companies ( Ovensa, Aeterna Laboratories, Atrium Innovations etc.).
Mr. Gagné has played a significant role in the growth of several Canadian companies abroad through his network of contacts in North and South America, Europe and Asia.
Sergei Tsurkan, Ph.D., MBA, strong economic and scientific background. The experience in scientific, product and
marketing development of several pharmaceutical companies (Sotex, Drugs technology, Maxpharm). Sergei is in charge in
supervising and management with Aimpila preclinical development, CA-62-test transfer and development. He has over 23 scientific publications.
Vera Gorbunova, Dr.M., professor (Russia/USA)- one of the
famous Russian scientists and practical doctor in the field of tumor desease chemotherapy. More than 400 hundred
articles, Hirsh index is 34. Member of the Cancer Society of
Russia (1971); European Society of Medical Oncologists (1991); French Federation of Oncology (1997); New York Academy of Sciences (1997); American Society of Clinical Oncology (1999) and others; honored with State Prize (2002).
Vera Gorbunobva helps our team in the field of clinical approach in development of our products.
Elena Yur'yevna Grigor'yeva
, Doctor of biology,
Head of the Laboratory of Radionuclide and Radiation Technologies in Experimental Oncology of the Russian Cancer Research Center.
2004 - Awarded I.V. Kurchatov premia for the best fundamental work, Membership in leading scientific communities: Association of Oncologists of Russia, Nanotechnological Society of Russia, Oncological Society of Molecular Visualization, Association of Medical Physicists of Russia. Elena has published about 80 articles.
Yelena helps us in pharmacokinetics studies and preclinical
Helen Treshchalina, Dr.M., Head of the Laboratory of T
umors Combined ChemoTherapy , Scientific Research Institute of Experimental Diagnostics and Therapy of
Tumors of the Russian Cancer Research Center. More than 250 scientific publications. Author of number in vivo
models in tumor treatment.
Helen helps us in studying of comparative activity of our complexes.
Evgueni Klinski Ph.D. (Canada/Russia) - member of American Associations of Pharmaceutical Scientists (AAPS), American Chemistry Society (ACS) and Control Release Society (CRS). He has more than 20 years of wide
experience in Canadian industrial pharmaceutical
company, such as formulation development,
pharmacokinetics/pharmacodynamics and drug metabolism.
Evgueni helps us in the field of proteins isolation. He is in charge in international know-how and technology transfer.
Market potential - More than $1 billion